{"id":31018,"date":"2025-11-07T18:05:42","date_gmt":"2025-11-07T17:05:42","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=31018"},"modified":"2025-11-07T18:10:18","modified_gmt":"2025-11-07T17:10:18","slug":"dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/","title":{"rendered":"DIM One HEALTH 2.0 : Appel \u00e0 projet 2025 &#8211; Investissement (2e session)"},"content":{"rendered":"\n<p>Les domaines d\u2019int\u00e9r\u00eat majeur (DIM), dispositifs de la politique r\u00e9gionale de recherche mis en place par la R\u00e9gion \u00cele-de-France, visent \u00e0 f\u00e9d\u00e9rer des r\u00e9seaux de laboratoires situ\u00e9s en \u00cele-de-France, agissant sur des domaines labellis\u00e9s cibl\u00e9s.&nbsp;<\/p>\n\n\n\n<p>L\u2019objectif du DIM One Health 2.0 est ainsi de promouvoir des travaux innovants \u00e0 vis\u00e9e fondamentale ou appliqu\u00e9e \u00ab One Health \u00bb int\u00e9grant les aspects de sant\u00e9 humaine, sant\u00e9 environnementale et sant\u00e9 animale cibl\u00e9es sur les agents infectieux et structur\u00e9s selon deux axes :&nbsp;<\/p>\n\n\n\n<ol>\n<li><strong>Origine :<\/strong> Causalit\u00e9\/\u00e9tiologie et \u00e9valuation des risques infectieux<\/li>\n\n\n\n<li><strong>Intervention :<\/strong> propositions de solutions op\u00e9rationnelles<\/li>\n<\/ol>\n\n\n\n<p>L\u2019appel \u00e0 projets 2025 permettra de financer :<\/p>\n\n\n\n<p>&#8211; Des allocations doctorales et post-doctorales et des manifestations scientifiques (projet fonctionnement)<\/p>\n\n\n\n<p>&#8211; L\u2019achat d\u2019\u00e9quipements et des mat\u00e9riels de recherche scientifique \u00e0 hauteur de 66% de leurs co\u00fbts le restant \u00e9tant \u00e0 fournir par le demandeur (projet investissement)<\/p>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-1 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"589\" src=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/11\/DIM-1-Health.png\" alt=\"\" class=\"wp-image-31019\" srcset=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/11\/DIM-1-Health.png 1024w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/11\/DIM-1-Health-300x173.png 300w, https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/11\/DIM-1-Health-768x442.png 768w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-bottom is-layout-flow wp-block-column-is-layout-flow\">\n<p><strong>En savoir plus et candidatez avant le 30 novembre 2025<\/strong><\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-white-color has-luminous-vivid-orange-background-color has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/doh2025invest.sciencescall.org\/?lang=fr\">En savoir plus<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Les domaines d\u2019int\u00e9r\u00eat majeur (DIM), dispositifs de la politique r\u00e9gionale de recherche mis en place par la R\u00e9gion \u00cele-de-France, visent \u00e0 f\u00e9d\u00e9rer des r\u00e9seaux de laboratoires situ\u00e9s en \u00cele-de-France, agissant sur des domaines labellis\u00e9s cibl\u00e9s.&nbsp; L\u2019objectif du DIM One Health 2.0 est ainsi de promouvoir des travaux innovants \u00e0 vis\u00e9e fondamentale ou appliqu\u00e9e \u00ab One [&hellip;]<\/p>\n","protected":false},"author":275,"featured_media":31019,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[6768,6631],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>DIM One HEALTH 2.0 : Appel \u00e0 projet 2025 - Investissement (2e session) - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DIM One HEALTH 2.0 : Appel \u00e0 projet 2025 - Investissement (2e session) - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-07T17:05:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T17:10:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/11\/DIM-1-Health.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"589\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"supportmlcom\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"supportmlcom\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/\"},\"author\":{\"name\":\"supportmlcom\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/126addd59310b0af2dd75ae8223445a5\"},\"headline\":\"DIM One HEALTH 2.0 : Appel \u00e0 projet 2025 &#8211; Investissement (2e session)\",\"datePublished\":\"2025-11-07T17:05:42+00:00\",\"dateModified\":\"2025-11-07T17:10:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/\"},\"wordCount\":171,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/11\/DIM-1-Health.png\",\"keywords\":[\"Actualit\u00e9s\",\"Appel \u00e0 Projet\"],\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/\",\"name\":\"DIM One HEALTH 2.0 : Appel \u00e0 projet 2025 - Investissement (2e session) - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/11\/DIM-1-Health.png\",\"datePublished\":\"2025-11-07T17:05:42+00:00\",\"dateModified\":\"2025-11-07T17:10:18+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/11\/DIM-1-Health.png\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/11\/DIM-1-Health.png\",\"width\":1024,\"height\":589},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"DIM One HEALTH 2.0 : Appel \u00e0 projet 2025 \u2013 Investissement (2e session)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/126addd59310b0af2dd75ae8223445a5\",\"name\":\"supportmlcom\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DIM One HEALTH 2.0 : Appel \u00e0 projet 2025 - Investissement (2e session) - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/","og_locale":"fr_FR","og_type":"article","og_title":"DIM One HEALTH 2.0 : Appel \u00e0 projet 2025 - Investissement (2e session) - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2025-11-07T17:05:42+00:00","article_modified_time":"2025-11-07T17:10:18+00:00","og_image":[{"width":1024,"height":589,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/11\/DIM-1-Health.png","type":"image\/png"}],"author":"supportmlcom","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"supportmlcom","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/"},"author":{"name":"supportmlcom","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/126addd59310b0af2dd75ae8223445a5"},"headline":"DIM One HEALTH 2.0 : Appel \u00e0 projet 2025 &#8211; Investissement (2e session)","datePublished":"2025-11-07T17:05:42+00:00","dateModified":"2025-11-07T17:10:18+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/"},"wordCount":171,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/11\/DIM-1-Health.png","keywords":["Actualit\u00e9s","Appel \u00e0 Projet"],"articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/","name":"DIM One HEALTH 2.0 : Appel \u00e0 projet 2025 - Investissement (2e session) - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/11\/DIM-1-Health.png","datePublished":"2025-11-07T17:05:42+00:00","dateModified":"2025-11-07T17:10:18+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/11\/DIM-1-Health.png","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2025\/11\/DIM-1-Health.png","width":1024,"height":589},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/dim-one-health-2-0-appel-a-projet-2025-investissement-2e-session\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Actualit\u00e9s","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/"},{"@type":"ListItem","position":4,"name":"DIM One HEALTH 2.0 : Appel \u00e0 projet 2025 \u2013 Investissement (2e session)"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/126addd59310b0af2dd75ae8223445a5","name":"supportmlcom"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-13 07:04:48","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/31018"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/275"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=31018"}],"version-history":[{"count":1,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/31018\/revisions"}],"predecessor-version":[{"id":31021,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/31018\/revisions\/31021"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/31019"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=31018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=31018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=31018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}